S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)

Xencor (XNCR) Stock Forecast, Price & News

$20.16
-0.19 (-0.93%)
(As of 09/22/2023 ET)
Compare
Today's Range
$20.12
$20.53
50-Day Range
$20.35
$25.39
52-Week Range
$20.12
$38.20
Volume
325,154 shs
Average Volume
333,561 shs
Market Capitalization
$1.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.20

Xencor MarketRank™ Forecast

Analyst Rating
Buy
3.08 Rating Score
Upside/​Downside
119.2% Upside
$44.20 Price Target
Short Interest
Bearish
9.24% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
0.55mentions of Xencor in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.87) to ($2.66) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

671st out of 968 stocks

Pharmaceutical Preparations Industry

304th out of 445 stocks


XNCR stock logo

About Xencor (NASDAQ:XNCR) Stock

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

XNCR Price History

XNCR Stock News Headlines

Xencor Director Awarded $844K Worth of Stock Options
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Xencor (NASDAQ:XNCR) Sets New 12-Month Low at $20.82
Xencor (NASDAQ: XNCR)
Barclays Remains a Sell on Xencor (XNCR)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
RBC Capital Remains a Buy on Xencor (XNCR)
Mizuho Securities Remains a Buy on Xencor (XNCR)
Xencor Reports Second Quarter 2023 Financial Results
Wedbush Sticks to Their Buy Rating for Xencor (XNCR)
What 6 Analyst Ratings Have To Say About Xencor
See More Headlines
Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

XNCR Company Calendar

Last Earnings
8/03/2023
Today
9/22/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XNCR
Employees
281
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$44.20
High Stock Price Forecast
$59.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+119.5%
Consensus Rating
Buy
Rating Score (0-4)
3.08
Research Coverage
12 Analysts

Profitability

Net Income
$-55,180,000.00
Net Margins
-112.46%
Pretax Margin
-111.86%

Debt

Sales & Book Value

Annual Sales
$164.58 million
Book Value
$12.14 per share

Miscellaneous

Free Float
57,601,000
Market Cap
$1.22 billion
Optionable
Optionable
Beta
0.72
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Bassil I. Dahiyat Ph.D. (Age 53)
    Co-Founder, CEO, Pres & Director
    Comp: $1.08M
  • Mr. John J. Kuch (Age 64)
    Sr. VP & CFO
    Comp: $660.75k
  • Dr. John R. Desjarlais Ph.D. (Age 59)
    Exec. VP of Research & Chief Scientific Officer
    Comp: $711.45k
  • Ms. Celia E. Eckert J.D. (Age 50)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $646.25k
  • Dr. Nancy Valente M.D. (Age 64)
    Exec. VP & Chief Devel. Officer
    Comp: $28.16k
  • Mr. Charles Liles
    Associate Director and Head of Corp. Communications & Investor Relations
  • Ms. Jennifer Sandoz
    VP of HR
  • Dr. Jeremy Grunstein Ph.D.
    Sr. VP of Bus. Devel.
  • Mr. Kirk Rosemark RAC (Age 58)
    Sr. VP of Regulatory Affairs & Quality Assurance
  • Mr. Eric P. Kowack
    Sr. VP of Program Leadership & Alliance Management













XNCR Stock - Frequently Asked Questions

Should I buy or sell Xencor stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XNCR shares.
View XNCR analyst ratings
or view top-rated stocks.

What is Xencor's stock price forecast for 2023?

12 equities research analysts have issued 1 year target prices for Xencor's stock. Their XNCR share price forecasts range from $36.00 to $59.00. On average, they anticipate the company's share price to reach $44.20 in the next year. This suggests a possible upside of 119.5% from the stock's current price.
View analysts price targets for XNCR
or view top-rated stocks among Wall Street analysts.

How have XNCR shares performed in 2023?

Xencor's stock was trading at $26.04 on January 1st, 2023. Since then, XNCR shares have decreased by 22.7% and is now trading at $20.14.
View the best growth stocks for 2023 here
.

When is Xencor's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our XNCR earnings forecast
.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) released its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.54. The biopharmaceutical company had revenue of $45.52 million for the quarter, compared to analysts' expectations of $26.25 million. Xencor had a negative trailing twelve-month return on equity of 18.14% and a negative net margin of 112.46%. The firm's revenue for the quarter was up 50.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.57) EPS.

What ETFs hold Xencor's stock?
What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Who are Xencor's major shareholders?

Xencor's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.75%), State Street Corp (5.12%), Dimensional Fund Advisors LP (2.60%), Geode Capital Management LLC (2.00%), Northern Trust Corp (1.23%) and Candriam S.C.A. (1.08%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert and John J Kuch.
View institutional ownership trends
.

How do I buy shares of Xencor?

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $20.14.

How much money does Xencor make?

Xencor (NASDAQ:XNCR) has a market capitalization of $1.22 billion and generates $164.58 million in revenue each year. The biopharmaceutical company earns $-55,180,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis.

How many employees does Xencor have?

The company employs 281 workers across the globe.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for the company is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at investors@xencor.com, or via fax at 626-305-0350.

This page (NASDAQ:XNCR) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -